Key terms
About OGEN
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OGEN news
Mar 18
7:08am ET
Oragenics appoints James Kelly as chief medical officer
Mar 05
7:53am ET
Oragenics prepares ONP-002 for clinical trials to treat concussion
Mar 01
4:26pm ET
Oragenics Inc Enhances Financial Standing with Equity Sale
Mar 01
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
9:12am ET
Oragenics Inc Announces Public Offering Pricing Details
Feb 28
6:12am ET
Oragenics Inc Announces Proposed Public Stock Offering
Feb 27
9:45pm ET
Oragenics 1.4M share Spot Secondary priced at $1.50
Feb 27
4:35pm ET
Oragenics announces common stock offering, no amount given
Feb 12
5:04pm ET
Oragenics Inc Announces Executive Leadership Transition
Feb 12
4:42pm ET
Oragenics, CEO Kimberly Murphy enter into separation agreement
Feb 02
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Jan 23
5:37pm ET
Oragenics terminates ‘at-the-market’ equity offering program
Jan 02
8:38am ET
Odyssey Health closes asset sale with Oragenics
No recent press releases are available for OGEN
OGEN Financials
Key terms
Ad Feedback
OGEN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OGEN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range